127 related articles for article (PubMed ID: 35715501)
21. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome.
Azar MM; Shin JJ; Kang I; Landry M
Expert Rev Mol Diagn; 2020 Nov; 20(11):1087-1097. PubMed ID: 32990479
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database.
Ceschi A; Noseda R; Palin K; Verhamme K
Front Pharmacol; 2020; 11():557. PubMed ID: 32425791
[TBL] [Abstract][Full Text] [Related]
23. Four cases of cytokine storm after COVID-19 vaccination: Case report.
Murata K; Nakao N; Ishiuchi N; Fukui T; Katsuya N; Fukumoto W; Oka H; Yoshikawa N; Nagao T; Namera A; Kakimoto N; Oue N; Awai K; Yoshimoto K; Nagao M
Front Immunol; 2022; 13():967226. PubMed ID: 36045681
[TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
25. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
26. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
Rogiers A; Pires da Silva I; Tentori C; Tondini CA; Grimes JM; Trager MH; Nahm S; Zubiri L; Manos M; Bowling P; Elkrief A; Papneja N; Vitale MG; Rose AAN; Borgers JSW; Roy S; Mangana J; Pimentel Muniz T; Cooksley T; Lupu J; Vaisman A; Saibil SD; Butler MO; Menzies AM; Carlino MS; Erdmann M; Berking C; Zimmer L; Schadendorf D; Pala L; Queirolo P; Posch C; Hauschild A; Dummer R; Haanen J; Blank CU; Robert C; Sullivan RJ; Ascierto PA; Miller WH; Stephen Hodi F; Suijkerbuijk KPM; Reynolds KL; Rahma OE; Lorigan PC; Carvajal RD; Lo S; Mandala M; Long GV
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468556
[TBL] [Abstract][Full Text] [Related]
27. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
[TBL] [Abstract][Full Text] [Related]
28. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
29. Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients - A case report and review of the literature.
Zhang Y; Wen X; OuYang Y; Hu Y; Fang X; Zhang J; Yuan Y
Heliyon; 2024 Jan; 10(2):e24380. PubMed ID: 38293388
[TBL] [Abstract][Full Text] [Related]
30. Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors.
Gwynn ME; DeRemer DL; Saunders KM; Parikh J; Bollag RJ; Clemmons AB
J Oncol Pharm Pract; 2020 Apr; 26(3):647-654. PubMed ID: 31474214
[TBL] [Abstract][Full Text] [Related]
31. Cytokine release syndrome induced by pembrolizumab: A case report.
Zhang X; Fu Z; Yan C
Medicine (Baltimore); 2022 Dec; 101(49):e31998. PubMed ID: 36626467
[TBL] [Abstract][Full Text] [Related]
32. COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies.
Goldman JD; Gonzalez MA; Rüthrich MM; Sharon E; von Lilienfeld-Toal M
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35658503
[TBL] [Abstract][Full Text] [Related]
33. Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.
Abid MB
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931473
[TBL] [Abstract][Full Text] [Related]
34. Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan.
Sato T; Kodama S; Kaneko K; Imai J; Katagiri H
Emerg Infect Dis; 2022 Jul; 28(7):1518-1520. PubMed ID: 35468049
[TBL] [Abstract][Full Text] [Related]
35. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Ishihara M; Kitano S; Kageyama S; Miyahara Y; Yamamoto N; Kato H; Mishima H; Hattori H; Funakoshi T; Kojima T; Sasada T; Sato E; Okamoto S; Tomura D; Nukaya I; Chono H; Mineno J; Kairi MF; Diem Hoang Nguyen P; Simoni Y; Nardin A; Newell E; Fehlings M; Ikeda H; Watanabe T; Shiku H
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35768164
[TBL] [Abstract][Full Text] [Related]
36. Cytokine release syndrome induced by immune checkpoint inhibitor treatment for uterine cervical cancer recurrence: A case report.
Sekimata M; Kinjo Y; Tohyama A; Murakami M; Hashiwaki S; Saito Y; Higami S; Hagimoto M; Taketomi R; Hoshino K; Harada H; Ueda T; Kurita T; Matsuura Y; Yoshino K
Oncol Lett; 2024 Jul; 28(1):331. PubMed ID: 38807673
[TBL] [Abstract][Full Text] [Related]
37. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
38. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
Awadalla M; Golden DLA; Mahmood SS; Alvi RM; Mercaldo ND; Hassan MZO; Banerji D; Rokicki A; Mulligan C; Murphy SPT; Jones-O'Connor M; Cohen JV; Heinzerling LM; Armanious M; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Rizvi MA; Sahni G; Lyon AR; Tocchetti CG; Mercurio V; Thuny F; Ederhy S; Mahmoudi M; Lawrence DP; Groarke JD; Nohria A; Fradley MG; Reynolds KL; Neilan TG
J Immunother Cancer; 2019 Feb; 7(1):53. PubMed ID: 30795818
[TBL] [Abstract][Full Text] [Related]
39. Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines.
Kang JH; Bluestone JA; Young A
Trends Immunol; 2021 Apr; 42(4):293-311. PubMed ID: 33714688
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy.
Wang H; Zhou F; Zhao C; Cheng L; Zhou C; Qiao M; Li X; Chen X
Front Immunol; 2022; 13():840313. PubMed ID: 35222434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
